ABBV US00287Y1091

Report

Real-time Estimate Cboe BZX - 10/21 02:17:30 pm
108.145	USD		-0.24%

06:19a	ASTRAZENECA : Puts Cancer Drug Trial On Hold Due To Safety Concerns	MT
10/18	ABBVIE : Receives CHMP Positive Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)	AQ
10/18	OYSTER POINT PHARMA : drug becomes first FDA-approved nasal spray to treat dry eyes	RE

Summary

Quotes 5-day view Delayed Quote.

Delayed Nyse

10/15/2021	10/18/2021	10/19/2021	10/20/2021	10/21/2021	Date
109.33(c)	107.43(c)	107.45(c)	108.41(c)	108.2	Last
4 634 513	7 949 357	4 614 876	5 627 072	2 765 768	Volume
+0.39%	-1.74%	+0.02%	+0.89%	-0.19%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2021	56 197 M - -
Net income 2021	12 472 M - -
Net Debt 2021	66 426 M - -
P/E ratio 2021	14,8x
Yield 2021	4,79%

Sales 2022	59 549 M - -
Net income 2022	15 047 M - -
Net Debt 2022	53 623 M - -
P/E ratio 2022	12,0x
Yield 2022	5,16%

Capitalization	192 B 192 B -
EV / Sales 2021	4,59x
EV / Sales 2022	4,12x
Nbr of Employees	48 000
Free-Float	98,0%

More Financials

Company

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human...

Sector

Pharmaceuticals

Calendar

10/29

Earnings Release

More about the company

Ratings of AbbVie Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

All news about ABBVIE INC.

06:19a	ASTRAZENECA : Puts Cancer Drug Trial On Hold Due To Safety Concerns	MT
10/18	ABBVIE : Receives CHMP Positive Opinion for Risankizumab (SKYRIZI) for the Treatment of Ad..	AQ
10/18	OYSTER POINT PHARMA : drug becomes first FDA-approved nasal spray to treat dry eyes	RE
10/15	REVANCE THERAPEUTICS : U.S. FDA declines to approve Revance's frown-line treatment	RE
10/15	ABBVIE : Says its Psoriatic Arthritis Drug Risankizumab Recommended by CHMP for Treatment ..	MT
10/15	AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of ..	CI
10/15	AbbVie Gets CHMP Positive Opinion for Risankizumab in Psoriatic Arthritis	DJ
10/14	PRESS RELEASE : Roche's Gazyvaro shorter 90-minute infusion time approved in Europe for pe..	DJ
10/14	ABBVIE INC. : Ex-dividend day for	FA
10/12	ABBVIE : Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Aware..	AQ
10/11	Health Care Stocks Sliding in Late Monday Trading	MT
10/11	Health Care Stocks Drifting Monday as Biotechs Climb	MT
10/08	ABBVIE : Upadacitinib (RINVOQ) Met Primary and Most Ranked Secondary Endpoints in Phase 3 ..	AQ
10/08	ABBVIE : RINVOQ (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 S..	AQ
10/07	ABBVIE : Gets Health Canada's Approval for Rinvoq to Treat Atopic Dermatitis	MT

More news

News in other languages on ABBVIE INC.

06:19a	AstraZeneca suspend l'essai d'un médicament contre le cancer en raison de problèmes de ..
10/11	Les actions du secteur de la santé en baisse lundi en fin de journée
10/11	Les actions du secteur de la santé à la dérive lundi alors que les biotechnologies grim..
10/07	AbbVie obtient l'approbation de Santé Canada pour le traitement de la dermatite atopiqu..
10/07	L'essai de phase 3 d'AbbVie sur l'upadacitinib pour le traitement potentiel des maux de..

More news

Analyst Recommendations on ABBVIE INC.

09/14	REGENXBIO : RBC Lifts Price Target on REGENXBIO to $55 From $50, Sees Eye Care Deal With A..	MT
09/02	ABBVIE : SVB Leerink Adjusts AbbVie PT to $142 From $148, Maintains Outperform Rating	MT
08/23	ABBVIE : Cowen Adjusts AbbVie's Price Target to $130 From $120, Reiterates Outperform Rati..	MT

More recommendations

Provided by Scoopnest.com

Analysis

China's biotech sector comes of age with big licensing deals, global ambitions